# Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00662740** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 220 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium/Salmeterol QD
- **DRUG:** Placebo
- **DRUG:** Salmeterol
- **DRUG:** Tiotropium/Salmeterol QD+ Salmeterol
- **DRUG:** Tiotropium (Spiriva®)

## Key facts

- **NCT ID:** NCT00662740
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04-15
- **Primary completion:** 2008-11-21
- **Final completion:** 2008-11-21
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662740, "Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00662740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*